#USA #Cambridge #Sirexatamab #Cypherpunk #Zcash

Cypherpunk Technologies Reports First Quarter 2026 Financial Results

Cypherpunk Technologies Inc. (Nasdaq: CYPH) recently disclosed its financial outcomes for the first quarter of 2026, which ended on March 31, revealing both significant advancements and challenges for the company.

President and CEO Douglas E. Onsi emphasized the company's mission to establish itself as a leading player in privacy technology, stating that the firm has bolstered its digital asset treasury strategy focused primarily on Zcash. This strategy has led to an increase in their treasury holdings, which now totals 314,185.70 ZEC, reflecting a deeper commitment to privacy-protecting assets in an increasingly digital and AI-driven world.

Financial Highlights:

• - Increased Investment in Zcash: Cypherpunk acquired an additional 10,279.30 ZEC for $5 million at an average price of $486.41 each since the previous update on April 15, 2026. This indicates a proactive approach in enhancing their digital asset portfolio, where they currently hold approximately 1.88% of Zcash's total circulating supply.

• - Investment in Development Labs: The company made a strategic move by investing $5 million into Zcash Open Development Labs (ZODL), an initiative aimed at strengthening Zcash's ecosystem and support mechanism. This marked Cypherpunk's first venture outside of Zcash into other technology sectors.

• - Launch of New Investor Dashboard: In a bid to enhance shareholder transparency, Cypherpunk has launched a revamped website and investor dashboard. This resource offers shareholders insights into the company's key metrics, ZEC holdings, and other critical updates pertaining to their privacy investments.

Leap Therapeutics Progress:

Cypherpunk's subsidiary, Leap Therapeutics, has also made strides in the biotechnology sector. Their drug, sirexatamab, received Fast Track designation from the FDA, aimed at treating patients with advanced colorectal cancer. The Fast Track program is designed to foster the development of medicines addressing serious conditions, thereby speeding up the path to review and approval.

Recent findings from AACR 2026 revealed promising results from studies utilizing a new plasma DKK1 biomarker assay linked with sirexatamab. Notably, at the conference, Leap presented data indicating that patients with high DKK1 levels derived significant benefits from the treatment, showcasing the potential for more individualized patient care in colorectal cancer.

Financial Results Summary:

Despite these advancements, Cypherpunk faced substantial financial losses in Q1 2026. The company reported a net loss of $77.2 million, significantly higher compared to the same period in the prior year, largely attributed to unrealized losses on the revaluation of their ZEC treasury holdings, which dropped in value. The price of ZEC plummeted from $508.09 to $240.47 during this quarter, impacting the company's financial metrics.

Research and development expenses were sharply reduced to $0.2 million compared to $12.9 million in Q1 2025, as many clinical trials concluded. However, general and administrative expenses increased to $4.7 million, influenced primarily by stock-based compensation for employees and directors.

Cash and cash equivalents stood at $6.7 million as of March 31, 2026, indicating a substantial decline from previous periods. Digital assets receivable, mainly from ZEC holdings, were recorded at $73.8 million.

Conclusion:

Cypherpunk Technologies Inc. remains steadfast in navigating the challenges and opportunities within the privacy technology and biotech landscapes. With aggressive investment strategies and continuous development in therapeutic technologies, Cypherpunk is positioning itself for future growth, irrespective of the financial hurdles currently faced. As digital economics evolve, the significance of privacy-centric solutions becomes even more critical, reinforcing the company's underlying mission.

For further details on Cypherpunk Technologies, visit their official website and investor relations page.